AbbVie
AbbVie Advances Solid Tumor Program with FDA Approval of Emrelis for Lung Cancer
AbbVie; Emrelis; FDA Approval; ADC; solid tumor; lung cancer; non-small cell lung cancer; c-Met overexpression; telisotuzumab vedotin-tllv; accelerated approval
AbbVie Commits $335M Upfront in Landmark siRNA Deal With ADARx
AbbVie; ADARx Pharmaceuticals; siRNA therapeutics; gene silencing; neuroscience; immunology; oncology; biotech partnerships; RNA technology; drug development
AbbVie Enters Obesity Market with $2.3 Billion Gubra Deal for Amylin Analog
AbbVie, Gubra, Obesity treatment, GUB014295 (GUBamy), Amylin analog, Weight loss drug, Pharmaceutical licensing deal
AbbVie and Xilio Therapeutics Forge $2.1 Billion Partnership for Novel Tumor-Activated Immunotherapies
AbbVie, Xilio Therapeutics, immunotherapy, tumor-activated, T cell engagers, collaboration, oncology, drug development
AbbVie and Xilio Therapeutics Collaborate on $2.1B Deal for Novel Tumor-Activated Immunotherapies
AbbVie, Xilio Therapeutics, T-cell engagers, tumor-activated immunotherapies, oncology, collaboration, biobucks deal
FDA Approves AbbVie’s Emblaveo for Complicated Intra-Abdominal Infections
Emblaveo, aztreonam, avibactam, antibiotic resistance, Gram-negative bacteria, intra-abdominal infections, AbbVie
Neomorph Secures $1.6 Billion Deal with AbbVie to Develop Molecular Glue Degraders for Oncology and Immunology
Neomorph, AbbVie, molecular glue degraders, oncology, immunology, protein degradation, drug development, biotechnology, pharmaceutical partnership.
Neomorph Secures Third Major Collaboration with AbbVie for Molecular Glue Degraders Worth Up to $1.64 Billion
Neomorph, AbbVie, molecular glue degraders, protein degradation, oncology, immunology, biotechnology, pharmaceutical collaboration
Key Presentations at JPM25: AbbVie, UCB, WuXi Biologics Highlight Industry Trends
JPM25, J.P. Morgan Healthcare Conference, AbbVie, UCB, WuXi Biologics, Biotech Trends, Healthcare Innovation
Denali and AbbVie’s ALS Candidates Fail Phase 2/3 Trials, Highlighting Challenges in ALS Research
ALS, Denali Therapeutics, AbbVie, Calico Life Sciences, HEALEY ALS Platform Trial, DNL343, fosigotifator, amyotrophic lateral sclerosis, clinical trials, drug development